GlassScriptPhysician profile
John L Redman
NPI 1356522759
$1,388.48
in general payments reported to CMS, 2019-2025
22 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $108 · 2021: $250 · 2022: $190 · 2023: $124 · 2024: $185 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $273.12 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $203.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.47 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $115.13 | 2019-2022 | |
| Axsome Therapeutics, INC. | $81.08 | 2025 | Auvelity |
| Exact Sciences Corporation | $79.99 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $53.31 | 2022-2024 | |
| Abbott Laboratories | $46.47 | 2021-2022 | |
| Organon LLC | $44.66 | 2022-2025 | Nexplanon |
| Pfizer INC. | $42.09 | 2019-2020 | |
| Amarin Pharma, INC. | $38.14 | 2020 | |
| Dexcom, INC. | $36.49 | 2024-2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $35.40 | 2025 | Jornay Pm |
| Inspire Medical Systems, INC. | $34.21 | 2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $27.79 | 2024-2025 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2021 | |
| Merck Sharp & Dohme LLC | $15.01 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.56 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $12.78 | 2019 | |
| Radius Health, INC. | $12.63 | 2019 | |
| Corium, LLC | $12.17 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Redman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.